RTSM leadership Endpoint Clinical recently released Elosity R3, a major update to its RTSM platform, signaling a continued investment in advanced randomization and trial supply management capabilities that can be leveraged to upsell enhanced software modules and services.

Global expansion With headquarters in Raleigh and offices across the US, EU, and Asia, Endpoint Clinical demonstrates a global footprint that supports multinational trials and region-specific implementations, presenting cross-border collaboration and localized support opportunities.

Industry recognition Being recognized as a Leader in the 2025 Everest Group RTSM PEAK Matrix reinforces credibility and may ease discussions with prospective customers seeking proven performance and vendor stability for critical trial operations.

Strategic growth hires Recent executive-level hires in US West and EMEA/APAC business development indicate a focus on expanding market coverage and customer acquisition, suggesting potential for co-selling, partnerships, and expanded account engagements.

Sustainability of impact Endpoint emphasizes proactive problem-solving and seamless trial integration, offering a compelling value proposition for midsize to large sponsors seeking risk reduction, efficiency gains, and smoother trial operations across multiple therapeutic areas.